
The official Cardiology PSN @SSCP_KSA Official Email: [email protected] | المجموعة التخصصية لعلاجات أمراض القلب | الجمعية السعودية للصيدلة السريرية
Joined October 2020
- Tweets228
- Following6
- Followers1.6K
- Likes38
Long-term LDL-C management made simpler for patients with HeFH! 💡
Phase 3 data for Inclisiran—an siRNA targeting hepatic PCSK9 synthesis—demonstrated robust and sustained LDL-C reduction with an infrequent dosing schedule and a favorable safety profile.
An encouraging approach to long-term LDL-C management through targeted siRNA therapy.
2
283
Promising Phase 3 data for Lerodalcibep in Heterozygous Familial Hypercholesterolemia (HeFH)! 🧬
As a novel small fusion protein targeting PCSK9, monthly administration demonstrated significant and sustained LDL-C reduction, with a safety profile comparable to placebo.
An encouraging step forward in the development of long-acting PCSK9-targeted therapies for HeFH.
203
Promising findings from the FOURIER trial evaluating evolocumab in patients with established ASCVD!
Adding the PCSK9 inhibitor evolocumab to statin therapy significantly reduced LDL-C levels and lowered the risk of major cardiovascular events, with a safety profile comparable to placebo.
A landmark trial supporting the benefits of intensive LDL-C lowering in patients with established ASCVD.
Alirocumab demonstrates promising results in heterozygous familial hypercholesterolemia (HeFH), delivering sustained LDL-C reductions and helping more patients achieve recommended LDL-C targets despite ongoing lipid-lowering therapy. 🧬
An encouraging advance in the management of HeFH and long-term cardiovascular risk.
Promising Phase 2 data for Lepodisiran in adults with elevated Lp(a)! 🧬
By targeting hepatic Lp(a) production using siRNA technology, Lepodisiran demonstrated potent and sustained reductions in Lp(a) levels, with a favorable safety profile.
An encouraging step forward in the development of targeted therapies for Lp(a) and future cardiovascular risk management.
Promising Phase 2 results for Olpasiran in patients with ASCVD and elevated Lp(a).
Using siRNA technology to target LPA expression in hepatocytes, Olpasiran demonstrated potent and sustained reductions in Lp(a) levels, with a favorable safety profile. 🧬
An encouraging step forward in the development of targeted therapies for Lp(a) and future cardiovascular care.
في اليوم العالمي لفرط كوليسترول الدم العائلي (FH) 🫀
نرفع الوعي بأهمية الفحص المبكر، والالتزام بالعلاج، واتباع نمط حياة صحي للمساعدة في تقليل مخاطر أمراض القلب والأوعية الدموية.
اعرف تاريخك العائلي، افحص مبكرًا، واعتنِ بصحة قلبك.
#KnowFH
#FHAwarenessDay
#FamilialHypercholesterolemia.
في اليوم العالمي لفرط كوليسترول الدم العائلي (FH) 🫀
نرفع الوعي بأهمية الفحص المبكر، والالتزام بالعلاج، واتباع نمط حياة صحي للمساعدة في تقليل مخاطر أمراض القلب والأوعية الدموية.
اعرف تاريخك العائلي، افحص مبكرًا، واعتنِ بصحة قلبك.
#KnowFH
#FHAwarenessDay
#FamilialHypercholesterolemia.
🐟 Fish oil is back in the spotlight.
The PISCES trial explores whether omega-3 supplementation can improve cardiovascular outcomes in patients undergoing maintenance hemodialysis.
🤖 Made with AI
SSCP Cardiology PSN retweeted
🫀 Can cardiac myosin inhibition benefit adolescents with obstructive HCM?
The phase 3 trial of mavacamten provides encouraging evidence for reducing LVOT obstruction while maintaining a favorable safety profile!
🤖 Made with AI
SSCP Cardiology PSN retweeted
🫀Not every lifelong therapy needs to be lifelong.
#SMARTDECISION evaluates whether β-blockers can be safely discontinued after myocardial infarction in selected patients.
A modern answer to a legacy practice. Take a look!
SSCP Cardiology PSN retweeted
🫀 #VESALIUSCV expands the role of #PCSK9i into high-risk primary prevention.
🏆 Among 6,129 high-risk patients, evolocumab significantly reduced first CV events:
📉 3-point MACE: 8.0% → 6.2% (ARR 1.8%, NNT 56)
📉 4-point MACE: 16.2% → 13.4% (ARR 2.8%, NNT 36)
🫀 Can cardiac myosin inhibition benefit adolescents with obstructive HCM?
The phase 3 trial of mavacamten provides encouraging evidence for reducing LVOT obstruction while maintaining a favorable safety profile!
🤖 Made with AI
🫀Not every lifelong therapy needs to be lifelong.
#SMARTDECISION evaluates whether β-blockers can be safely discontinued after myocardial infarction in selected patients.
A modern answer to a legacy practice. Take a look!
🫀 #VESALIUSCV expands the role of #PCSK9i into high-risk primary prevention.
🏆 Among 6,129 high-risk patients, evolocumab significantly reduced first CV events:
📉 3-point MACE: 8.0% → 6.2% (ARR 1.8%, NNT 56)
📉 4-point MACE: 16.2% → 13.4% (ARR 2.8%, NNT 36)
LOVE CARDIOLOGY? WE WANT YOU! ❤️
Become a volunteer with the SSCP Cardiology PSN and be part of a community dedicated to education, innovation, and excellence in cardiovascular care.
🚀 Learn
🤝 Connect
⭐ Lead
❤️ Make an Impact
Sign up! forms.gle/wbGvBoUX3H7p2NsMA
As we conclude today’s scientific meeting, we extend our sincere appreciation to the organizing team whose dedication, professionalism, and teamwork were instrumental in delivering a successful and impactful program.
Thank you for your efforts in making this event a success! 🫀
The Junior Pharmacist Interactive Engagement Challenge featured an interactive audience questions competition, fostering active participation and knowledge exchange, and was led by Dr. Reem Bahmaid and Dr. Mahasen Alharbi.
The Symposium for the GOLDEN Sponsor was delivered by Dr. Yaser Nemshah, highlighting key perspectives and insights relevant to current and emerging therapeutic approaches in the management of cardiac amyloidosis🫀.
1
1
524



















